- Market Capitalization, $K 67,688
- Shares Outstanding, K 22,638
- Annual Sales, $ 39,850 K
- Annual Income, $ 17,890 K
- 60-Month Beta 0.27
- Price/Sales 1.73
- Price/Cash Flow 3.55
- Price/Book 1.27
|Period||Period Low||Period High||Performance|
| || |
+0.12 (+4.18%)since 11/01/23
| || |
-0.93 (-23.72%)since 09/01/23
| || |
-0.24 (-7.43%)since 12/01/22
Reata (RETA) incurs wider-than-expected loss in the first quarter. The company discontinues the development of bardoxolone methyl for diabetic kidney disease.
TEVA reports mixed Q1 results, missing earnings estimates but beating the same for revenues. Stock falls.
Amicus (FOLD) incurs wider-than-expected loss in the first quarter. Revenues, however, beat estimates. The company reiterates its 2023 guidance.
Halozyme (HALO) first-quarter earnings and revenues miss estimates. The company reiterates its guidance for 2023.
Emergent (EBS) reports wider-than-expected first-quarter loss. The company updates its 2023 guidance for selected categories.
Axsome (AXSM) incurs a narrower-than-expected loss in 1Q23. Its revenues beat estimates and stock gains.
CRISPR Therapeutics (CRSP) provides updates for its gene therapy candidates.
Intra-Cellular (ITCI) first-quarter earnings and revenues beat estimates. The company reiterates its previously issued guidance for 2023.
If you are looking for stocks that are well positioned to maintain their recent uptrend, Ocuphire Pharma, Inc. (OCUP) could be a great choice. It is one of the several stocks that passed through our "Recent...
Puma Biotechnology (PBYI) earnings and sales beat estimates in Q1. Stock rises in after-hours.